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AnalysisThe Aftermath of Scientific Fraud
Scientists who have come face to face with scientific misconduct consider its 
consequences years later.Scientific fraud became front-page 
news at the end of last year, when 
South Korean stem cell researcher, 
Woo Suk Hwang, admitted to fab-
ricating data about cloned human 
embryonic stem cell lines that he 
claimed were created from patients. 
Much of the press coverage focused 
on the fallout of Hwang’s actions on 
the public’s trust in science and the 
already fragile image of stem cell 
research. But looking beyond the 
headlines, the repercussions of sci-
entific misconduct also resonate on 
a more personal level.
“It was my darkest professional 
hour when I found out that a talented 
student who I had great hopes for 
systematically manipulated data. 
It changed me forever,” says Fran-
cis Collins, director of the National 
Human Genome Research Institute 
(NHGRI) at the National Institutes of 
Health (NIH). Collins retracted five 
papers published in 1995 and 1996 
about a possible genetic cause of 
leukemia when Amitav Hajra, a grad-
uate student working in his labora-
tory, first at the University of Michi-
gan and then at the NIH, admitted to 
having fabricated the results.
The incident derailed Hajra’s plans 
of becoming a physician-scientist; he 
was barred from applying for federal 
grants for four years and was denied 
both a doctoral and medical degree 
from the University of Michigan. But 
the incident also harmed others. “In 
the short run it had a profoundly nega-
tive impact on other people in the lab, 
especially the post-doc working most 
closely with Hajra. He wondered for 
some time whether his career had just 
gone south,” says Collins. “Eventually 
he did recover but it was an enormous 
challenge. It took several years of 
doing experiments over.” The former 
postdoctoral fellow, Paul Liu, is now a 
senior investigator at NHGRI.Collins was praised for the forth-
right way he handled the case of 
misconduct, which had been dis-
covered by a reviewer of a paper 
that Hajra had submitted to the 
journal Oncogene. But the inci-
dent changed the way that Collins 
oversees his research group. “It 
caused me to become more skep-
tical, which is something I am not 
entirely happy about,” he says. “I 
always had a skeptical eye in terms 
of looking at the technical aspects 
of data, but until this awful experi-
ence that did not include a concern 
about whether the data were real or 
fabricated. Now it does.”
Dealing with Misconduct
Cases of possible scientific miscon-
duct involving research funded by 
the NIH and other agencies within the 
US Department of Health and Human 
Services (HHS) are brought to the 
attention of the Office of Research 
Integrity (ORI) in Rockville, Maryland 
by the institute where the incident 
occurred. ORI, established in 1992 
as part of the HHS, steps in to review 
the findings of the institutional inves-
tigation and to determine a punitive 
action for those responsible. The 
most common action taken by ORI 
consists of barring the guilty individ-
ual from receiving federal funds for 3 
to 4 years, but the extent of the pun-
ishment depends on several criteria, 
such as the nature of the misconduct 
and who was responsible.
Although the integrity of Collins 
and Liu was never questioned by the 
University of Michigan or by the NIH, 
Steven Burden was less fortunate. 
In 1989, Burden became the inno-
cent target of an investigation by the 
Massachusetts Institute of Technol-
ogy (MIT) in Boston, where he was 
an associate professor. Burden dis-
covered he could not replicate data Cell 124,in a study his group had published 
in the journal Nature (the first author 
of the paper having recently left the 
lab). “As we were following-up on 
experiments reported in the Nature 
study we found disparities between 
the contents of tubes containing 
reagents used in the earlier experi-
ments and the labeling of these 
tubes,” recalls Burden. “Initially, 
these errors appeared innocent and 
possibly innocuous, but they took on 
a more ominous note when I asked 
[the former postdoc] to return to MIT 
to clear up the confusion.” Two days 
after returning to MIT, the postdoc 
admitted himself to a psychiatric hos-
pital and was not available while the 
experiments were being repeated. It 
took Burden and others in the labo-
ratory three months to determine 
that the published data were wrong, 
to send letters to colleagues whose 
work might be directly affected, and 
to submit a correction to Nature.
Burden points out that although 
NIH’s Office of Scientific Integrity—
the predecessor of ORI—completely 
cleared him of any wrongdoing, the 
investigation forced him to leave MIT. 
“It was a difficult struggle to look for 
a position under the veil of the inves-
tigation,” emphasizes Burden, who 
is now a tenured professor at the 
Skirball Institute at New York Uni-
versity Medical School in New York 
City. “The one redeeming experience 
from this exceedingly distressful 
period was the heartening support I 
received from colleagues at MIT and 
elsewhere, which was critical to con-
tinue with my career.”
The case was never fully resolved, 
but in Burden’s opinion “there is little 
question it was fraud. After compar-
ing the data reported by [the former 
postdoc] and the data we subse-
quently collected, I had little doubt 
that the data were fabricated.” Bur- March 10, 2006 ©2006 Elsevier Inc. 873
den’s former postdoc spent several 
years in laboratories at the University 
of California, San Francisco and at 
Guy’s Medical School in London, until 
problems arose, in one case involving 
experiments being sabotaged.
Blowing the Whistle
In the cases of both Burden and Col-
lins, the problematic data were gen-
erated by a postdoctoral fellow and 
a graduate student, respectively. 
But what happens when the person 
heading the laboratory is the one 
suspected of fraud? “In cases where 
the PI is responsible for misconduct, 
the lab may be shut down putting 
students and postdocs in jeopardy. 
This causes serious morale prob-
lems during the investigation. It is 
very harmful for innocent people,” 
says Chris Pascal, director of ORI.
In one of the biggest cases of mis-
conduct in German history, Fried-
helm Herrmann and Marion Brach, 
two investigators at the Max Del-
bruck Centre for Molecular Medicine 
in Berlin, retracted 11 papers pub-
lished between 1991 and 1999 con-
taining data they admitted had been 
fabricated. Eberhard Hildt, currently 
an investigator at the Robert Koch-
Institut in Berlin, was a postdoctoral 
fellow in the lab when allegations 
of misconduct were raised against 
Herrmann and Brach in 1997. “The 
consequence for me was that I had 
to leave the lab,” he says. Others 
were in a more difficult position. “The 
students had the problem of how to 
finish their thesis with no funding. In 
the end, the university provided for 
them,” says Hildt. Today the case 
is far behind him, but he is aware of 
the dangers involved. “I try to avoid 
any kind of structure that would pro-
mote fabrication. I tell students not 
to have any result in mind that they 
have to demonstrate. We just do an 
experiment and see what happens,” 
he says.
Pointing the finger at an estab-
lished scientist is potentially dam-
aging to the person who takes the 
initiative. “The whistleblower is usu-
ally on the losing side,” says Walter F. 
DeNino. In 2000, he was a research 
assistant in the laboratory of Eric 874 Cell 124, March 10, 2006 ©2006 ElsPoehlman, an expert on menopause 
at the University of Vermont College 
of Medicine (UVM), when he alerted 
university officials to discrepan-
cies in one of the patient data sets 
Poehlman was using. “Other people 
had noticed something was wrong 
but no one wanted to speak out,” he 
says. “To be honest, legal protec-
tion for the whistleblower is limited. 
I was forced to find legal counsel to 
deal with the after effects. Poehl-
man was very aggressive during the 
investigation.” DeNino left UVM to 
take courses at Columbia University 
in New York City and has applied to 
medical school there. “[The incident] 
did not deter me from my plans, but 
it did make me more interested in 
 ethics,” he explains.
Poehlman was barred for life from 
obtaining federal research grants, 
in addition to facing hefty fines and 
possible jail time. The researcher 
pleaded guilty in March 2005 to 
having falsified research in 17 grant 
applications (amounting to about 
$2.9 million in funding from the NIH 
and the US Department of Agricul-
ture) and in 10 research articles pub-
lished from 1992 to 2002, all of which 
were retracted or corrected. In Sep-
tember 2001, while the investigation 
was under way, Poehlman resigned 
from UVM and moved to the Univer-
sity of Montreal. He subsequently 
left this position in January 2002 and 
has been living in Canada since. He 
faces a plea hearing and sentencing 
“in the next several months,” says 
ORI’s Pascal. Russell Tracy, asso-
ciate dean for research and aca-
demic affairs at UVM, says the case 
“caused a great deal of sorrow and 
pain to a relatively large number of 
people who knew Eric Poehlman and 
liked him. A smaller number of peo-
ple had close professional ties. Their 
concern was that it would affect their 
ability to be scientists.”
Colleagues and Collaborators
Being the coauthor of a paper that 
is retracted can be damaging, 
especially in the early stages of a 
person’s career. In cases where 
collaborators are not aware that 
data in a study were falsified, ORI evier Inc.does not hold them accountable 
of wrongdoing. “Our view is a legal 
issue. We will not blame them and 
will not hold them responsible,” says 
Pascal. But the UK-based Commit-
tee on Publication Ethics (COPE) 
has a somewhat stricter view. “At 
COPE we would say any author 
has a responsibility of taking pub-
lishing ownership. There may be a 
situation where one author falsified 
data or has a conflict of interest and 
others are not aware of it. Perhaps 
the coauthors did not know the full 
picture. They should then withdraw 
their names from the publication,” 
says Sabine Kleinert, a member of 
COPE and an executive editor of 
the medical journal The Lancet.
The question of authorship was 
recently highlighted in the case of 
Gerald P. Schatten, a biologist at the 
University of Pittsburgh. His name 
appeared last in the list of authors 
of the now retracted 2005 Science 
paper on cloned human embryonic 
stem cells by Hwang and his team 
from Seoul National University in 
South Korea. Schatten was recently 
found guilty, by a panel at the Uni-
versity of Pittsburgh, of “research 
misbehavior” for allowing himself be 
listed as a senior coauthor when he 
had performed none of the experi-
ments and had not verified the data. 
Science is now conducting its own 
investigation to examine how the 
Korean stem cell papers were han-
dled and the journal’s policies in gen-
eral; these findings are expected to 
be reported in April.
Setting the Record Straight
Most countries outside the United 
States do not have an independent 
institute like ORI dedicated to handling 
scientific misconduct but instead use 
an ad hoc system for investigating 
possible misconduct cases. Ulf Rapp 
of the University of Würzburg, Ger-
many headed a task force commis-
sioned by the DFG, Germany’s main 
funding agency, to investigate the 
Herrmann-Brach case. He says the 
commission found that at least 94 
papers, including reports of clinical 
trials, had been manipulated and sev-
eral people were probably involved. 
The Herrmann-Brach case and the 
commission’s findings prompted 
the DFG to establish new guidelines 
for dealing with scientific miscon-
duct. Every publicly funded German 
research institute is now required to 
sign a copy of the guidelines and to 
agree to uphold them.
Rapp was disappointed with 
the ultimate outcome of the case. 
According to him, only 11 papers (out 
of the 94 thought to contain falsified 
data) were retracted or corrected, 
and the scientists involved in the 
research, apart from Herrmann and 
Brach, continue to work. “From the 
start all I wanted to do was set the 
scientific record straight. It was just 
about the papers,” Rapp says.
But setting the record straight 
may be more challenging than antici-
pated. When a retraction is published 
it appears in PubMed (the online 
database of biomedical and life sci-
ences journal literature) linked to the 
original paper, thereby alerting sci-
entists to the problem. John Budd, 
professor of information science at 
the University of Missouri-Columbia 
has, however, found that retracted 
papers continue to be cited in the 
scientific literature at rates compara-
ble to those for nonretracted papers. “There is essentially no difference,” 
says Budd. “My guess is that peo-
ple become aware of the published 
works through mechanisms other 
than databases.”
Lies, Big and Small
It may be a scientist’s worst night-
mare, but by most accounts, outright 
fraud is rare. Since 1992, more than 
2700 allegations of possible miscon-
duct were brought to ORI’s atten-
tion, resulting in over 160 findings of 
actual misconduct. In a recent study, 
Brian Martinson, an investigator with 
the HealthPartners Research Foun-
dation in Minneapolis, gathered 
responses from 3,247 NIH-funded 
researchers to a mailed survey about 
different ethical behaviors. Based 
on the results published in Nature 
last year, 0.3 percent of scientists 
admitted to fabricating research 
data and 1.4 percent to plagiarism. 
“These behaviors are not the lion’s 
share,” says Martinson. However, 33 
percent of those surveyed admitted 
to “lesser” offenses, such as inap-
propriately including their names 
as authors on papers where they 
had made little or no contribution, 
changing a study’s design to satisfy 
a sponsor, overstating results, with-Cell 124,holding findings, and so on. Discus-
sions in focus groups of 51 scien-
tists revealed that most of them “are 
uncomfortable with these behaviors 
but say they must do them to survive 
in their work,” says Martinson.
So, is it possible to prevent mis-
conduct in scientific research? “If 
someone is intent on fabricating data 
there is not much you can do,” says 
Burden. But Burden is now even more 
cautious about the people he recruits 
to work in his lab. “If I am uneasy 
about a person, I do not offer them 
a position,” he says. “It is a shame 
because I think there should be a 
diversity of personalities in science, 
but I am consciously risk averse.” He 
also believes that having a focused 
research program helps him to avoid 
mistakes and to identify them rapidly 
when they do occur. “There is conti-
nuity in terms of the projects we work 
on, so there is a good chance we will 
pick up errors ourselves.” Talking to 
students and postdoctoral fellows 
about safeguarding the integrity of 
data may also help. “Anyone who 
comes to my lab is aware of the inci-
dent,” says Collins. “That is a small 
silver lining of the case. As awful as 
it was, I use every opportunity to tell 
people about it.”
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